Sgk1 inhibitory compositions and methods
OwnerErik Blackwood, Christopher Glembotskiinventors
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a fusion peptide comprising an inactive peptide fragment of Serum/Glucocorticoid Regulated Kinase 1 (SGK1) and a cell internalization sequence, wherein the SGK1 fragment is capable of binding and sequestering glucocorticoid-induced leucine zipper (GILZ). In some embodiments, the inactive peptide fragment of SGK1 binds and sequesters GILZ, preventing it from binding and extending the half-life of endogenous SGK1. Also disclosed herein is a method for treating a disease associated with aberrant Serum/Glucocorticoid Regulated Kinase 1 (SGK1) activity in a subject that involves administering to the subject an agent that blocks the binding of endogenous SGK1 to endogenous glucocorticoid-induced leucine zipper (GILZ).
Claims14
A fusion peptide comprising a peptide fragment of Serum/Glucocorticoid Regulated Kinase 1 (SGK1) and an internalization sequence,
- wherein the peptide fragment comprises at least 10 consecutive amino acids of SEQ ID NO:1, or a variant thereof having at least 85% sequence identity to SEQ ID NO:1.
A method for treating a disease associated with aberrant Serum/Glucocorticoid Regulated Kinase 1 (SGK1) activity in a subject, comprising administering to the subject an agent that blocks the binding of endogenous SGK1 to endogenous glucocorticoid-induced leucine zipper (GILZ).
Dependencies are inferred from the claim text.